Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 24-month pharmacovigilance extension of cannabidiol + delta-9-tetrahydrocannabinol for Parkinson's disease
RBR-92v86nnPhase 4Completed
- Sponsor
- Universidade Federal de Santa Catarina
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cannabidiol and dronabinol in Parkinson's disease (PD), sponsored by Universidade Federal de Santa Catarina. Started Jan 2024; status: completed.
02
Drugs
cannabidioldronabinol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on RBR-92v86nn.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-92v86nn.